Circulating ghrelin level is higher in HNF1A–MODY and GCK–MODY than in polygenic forms of diabetes mellitus

Endocrine

Volumn 50, Issue 3, 2015, Pages 643-649

  Nowak, Natalia ^a,b   Hohendorff, Jerzy ^a,c   Solecka, Iwona ^c   Szopa, Magdalena ^a,c   Skupien, Jan ^a,c   Kiec Wilk, Beata ^a,c   Mlynarski, Wojciech ^d   Malecki, Maciej T ^a,c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JOSLIN DIABETES CENTER   (United States)

^c UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

GCK MODY; Ghrelin; HNF1A MODY; T1DM; T2DM

Indexed keywords

BIOLOGICAL MARKER; GHRELIN; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BINDING SITE; BODY MASS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIMERIZATION; DISEASE CLASSIFICATION; DNA BINDING; FEMALE; GCK GENE; GENE MUTATION; GENETIC ASSOCIATION; HNF1A GENE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TRANSACTIVATION; BLOOD; CASE CONTROL STUDY; GENETICS; MIDDLE AGED;

ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GHRELIN; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; MALE; MIDDLE AGED;

EID: 84949092251     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0627-5     Document Type: Article

References (32)

1. S. Ellard, K. Colclough, Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum. Mutat. 27, 854–869 (2006)
2. D.T. Odom, N. Zizlsperger, D.B. Gordon et al., Control of pancreas and liver gene expression by HNF transcription factors. Science 303, 1378–1381 (2004)
3. A. D’Angelo, O. Bluteau, M.A. Garcia-Gonzalez et al., Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium. Development 137, 1573–1582 (2010)
4. M.S. Taylor, Y. Hwang, P.Y. Hsiao et al., Ghrelin O-acyltransferase assays and inhibition. Methods Enzymol. 514, 205–228 (2012)
5. S. Park, H. Jiang, H. Zhang et al., Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release. Proc. Natl. Acad. Sci. U.S.A. 109, 19003–19008 (2012)
6. O. Ukkola, Ghrelin in type 2 diabetes mellitus and metabolic syndrome. Mol. Cell. Endocrinol. 340, 26–28 (2011)
7. F. Broglio, C. Gottero, F. Prodam et al., Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J. Clin. Endocrinol. Metab. 89, 3062–3065 (2004)
8. C. Gauna, P. Delhanty, L. Hofland et al., Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J. Clin. Endocrinol. Metab. 90, 1055–1060 (2005)
9. A. Benso, D. St-Pierre, F. Prodam et al., Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. Eur. J. Endocrinol. 166, 911–916 (2012)
10. R.M. Mosa, Z. Zhang, R. Shao et al., Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases. Endocrine (2015). doi:10.1007/s12020-015-0531-z
11. F. Brial, C. Lussier, F. Boudreau, Lack of HNF1A/MODY promotes diabetes through enteroedocrine ghrelin upregulation. [Abstract]. Gastroenterology 144(Suppl 1), 344 (2013)
12. C.R. Lussier, F. Brial, S.A. Roy et al., Loss of hepatocyte-nuclear-factor-1alpha impacts on adult mouse intestinal epithelial cell growth and cell lineages differentiation. PLoS ONE 5, e12378 (2010)
13. C. Bellanne-Chantelot, C. Carette, J.P. Riveline et al., The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes 57, 503–508 (2008)
14. L.W. Harries, S. Ellard, A. Stride et al., Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum. Mol. Genet. 15, 2216–2224 (2006)
15. J. Bochenski, G. Placha, K. Wanic et al., New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals. Diabetes 55, 2626–2630 (2006)
16. C. Prudom, J. Liu, J. Patrie et al., Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels. J. Clin. Endocrinol. Metab. 95, 2351–2358 (2010)
17. E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988)
18. M. Nakazato, N. Murakami, Y. Date et al., A role for ghrelin in the central regulation of feeding. Nature 409, 194–198 (2001)
19. J. Tong, R.L. Prigeon, H.W. Davis et al., Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 59, 2145–2151 (2010)
20. T. Shiiya, M. Nakazato, M. Mizuta et al., Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J. Clin. Endocrinol. Metab. 87, 240–244 (2002)
21. M. Tschop, C. Weyer, P.A. Tataranni et al., Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001)
22. S.M. Poykko, E. Kellokoski, S. Horkko et al., Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553 (2003)
23. C. Holdstock, J. Ludvigsson, F.A. Karlsson, Abnormal ghrelin secretion in new onset childhood type 1 diabetes. Diabetologia 47, 150–151 (2004)
24. G.A. Martos-Moreno, V. Barrios, L. Soriano-Guillen et al., Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy. Eur. J. Endocrinol. 155, 757–761 (2006)
25. J. Tong, R.L. Prigeon, H.W. Davis et al., Physiologic concentrations of exogenously infused ghrelin reduces insulin secretion without affecting insulin sensitivity in healthy humans. J. Clin. Endocrinol. Metab. 98, 2536–2543 (2013)
26. C. Meyer, Final answer: ghrelin can suppress insulin secretion in humans, but is it clinically relevant? Diabetes 59, 2726–2728 (2010)
27. K.R. Owen, J. Skupien, M.T. Malecki, The clinical application of non-genetic biomarkers for differential diagnosis of monogenic diabetes. Diabetes Res. Clin. Pract. 86(Suppl 1), 15–21 (2009)
28. S.A. Mughal, R. Park, N. Nowak et al., Apolipoprotein M can discriminate HNF1A–MODY from type 1 diabetes. Diabet. Med. 30, 246–250 (2013)
29. G. Thanabalasingham, N. Shah, M. Vaxillaire et al., A large multi-centre european study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 54, 2801–2810 (2011)
30. G. Thanabalasingham, J.E. Huffman, J.J. Kattla et al., Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 62, 1329–1337 (2013)
31. P.J. Tomasik, K. Sztefko, M. Pizon, The effect of short-term cold and hot exposure on total plasma ghrelin concentrations in humans. Horm. Metab. Res. 37, 189–190 (2005)
32. A. Stengel, L. Wang, Y. Tache, Stress-related alterations of acyl and desacyl ghrelin circulating levels: mechanisms and functional implications. Peptides 32, 2208–2217 (2011)